Independent consultant, owner and CEO of Granzer Regulatory Consulting & Services GmbH with currently 50+ employees. Granzer is focusing on global drug development and regulatory affairs with special considerations for orphan drugs. Ulrich Granzer has major experience with biotech products (proteins, cell-based therapies, gene therapies, oligonucleotides, vaccines, phages) and small molecules. A mainstay of his work is dedicated to orphan drugs.
He holds a PhD in pharmaceutical chemistry. Prior to being independent he held senior positions at Glaxo, BASF pharma Knoll, and Bayer.
He has a track record of working on more than 300 new molecular entities (small molecules, proteins incl. antibodies, oligonucleotides, gene therapies, cell therapies). Recently he and his firm supported the first approval of a mRNA vaccine against Covid 19.